Key Drivers
- Strong Margins
- High Leverage
- Cash Conversion
AIAI Summary
Alnylam should now be viewed less as a speculative RNAi platform and more as a high-margin, cash-generating specialty pharma franchise whose upside depends on sustaining Amvuttra/ATTR-CM growth and converting strong earnings into durable cash flow, but the investment remains exposed to heavy TTR concentration, rich valuation, and fragile market momentum.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Margins
- •High Leverage
- •Cash Conversion
ALNY shows strong profitability, solid cash generation, and good liquidity, but high leverage, negative retained earnings, earnings-quality concerns, and a very rich valuation limit upside.
Price Behavior
Key Price Behavior Insights:
- •Lower-high pattern
- •Failed rebound
- •$285 floor
ALNY remains technically weak over the last month, with lower highs/lows, failed rebounds below $303, and only tentative support near $285.
Former support at $308–$314 flipped into resistance, and rebounds stalled near $295–$303
Sentiment & News
Key News Insights:
- •Amvuttra Surge
- •TTR Confidence
- •Clinical Validation
Alnylam posted a strong Q1 beat with 96% revenue growth driven by Amvuttra, while continued clinical data and access gains reinforce confidence in its TTR amyloidosis growth story.
The results and updates are supportive for Alnylam's outlook, signaling sustained commercial momentum and strengthening its position in the ATTR-CM market
Similar Companies in Healthcare
Other companies in the same sector with AI ratings